Nurcan Kırıcı Berber

Nurcan Kırıcı Berber

Auto-generated profile, based on publicly available information

Nurcan Kırıcı Berber

Department of Pulmonary Medicine, Faculty of Medicine, Malatya Turgut Özal University, Malatya, Turkey

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2022 in Journal of Medical Virology
Verified
Journal Article
Closed access
EIErdal İn
Erdal İn
AGAyşegül Altıntop Geçkil
Ayşegül Altıntop Geçkil
GKGürkan Kavuran
Gürkan Kavuran
MŞMahmut Şahin
Mahmut Şahin
NBNurcan K. Berber
Nurcan K. Berber
MKMutlu Kuluöztürk
Mutlu Kuluöztürk

19 January 2023 in Journal of Medical Virology
Verified
Journal Article
Closed access
NBNurcan Kırıcı Berber
Nurcan Kırıcı Berber
AGAyşegül Altıntop Geçkil
Ayşegül Altıntop Geçkil
NANazife Özge Altan
Nazife Özge Altan
TKTuğba Raika Kıran
Tuğba Raika Kıran
ÖOÖnder Otlu
Önder Otlu
EIErdal İn
Erdal İn

18 July 2025 in Scientific Reports
Verified
Journal Article
Open access
OOOnder Otlu
Onder Otlu
MEMehmet Erdem
Mehmet Erdem
TKTugba Raika Kıran
Tugba Raika Kıran
FİFeyza İnceoğlu
Feyza İnceoğlu
AGAyşegül Altıntop Geçkil
Ayşegül Altıntop Geçkil
EIErdal İn
Erdal İn
Oxygen-regulated protein 150 (ORP150) is a chaperone found in the endoplasmic reticulum (ER) induced by ER stress, oxidative stress, glutamate toxicity, ischemia, and hypoxia. Increased expression of ORP150 protects the cells by stopping ER stress, maintaining calcium balance, and delaying apoptosis. In this study, we aim to investigate serum ORP150 amount in patients with different severity levels of obstructive sleep apnea (OSA). Forty-nine patients (25 of severe and 24 of mild-moderate), and 23 healthy controls were included in the study. Routine biochemical measurements and serum ORP150 measurements of all groups and sleep quality measurements of OSA groups were obtained. ELISA was used to measure ORP150 levels in serum samples. In addition, ROC analysis was performed to determine the diagnostic power of the ORP150 parameter. There are significant differences between all three groups in terms of ORP150 values (severe OSA: 8.03 ± 0.4 ng/mL; mild-moderate OSA: 5.54 ± 0.47 ng/mL; control: 4.41 ± 0.25 ng/mL, p < 0.017). The highest ORP150 level belongs to the severe OSA group and there is a direct correlation between the severity of the disease and ORP150 levels. ORP150 value is a distinguishing parameter for OSA and the cut-off value of ORP150 was observed as 7.14 ng/mL. We concluded that serum ORP150 levels can be a differential diagnostic parameter in OSA patients and that disease severity can be determined by serum ORP150 measurement.

21 January 2021 in Journal of Health Sciences and Medicine
Verified
Journal Article
Open access
PDF file
NBNurcan Kirici Berber Berber
Nurcan Kirici Berber Berber
ÖUÖzkan Ulutaş
Özkan Ulutaş
ASAhmet Sarıcı
Ahmet Sarıcı
AYAslı YILDIRIM
Aslı YILDIRIM
ÖÇÖzlem Çağaşar
Özlem Çağaşar
IBİ̇lhami Berber
İ̇lhami Berber
Background: To date, several studies were published about clinical features and laboratory values associated with disease severity in covid 19 patients. We aimed to show the relationship between disease severity and clinical and laboratory characteristics of the patients as a single center experience. Methods: Clinical features and laboratory data of fifty patients diagnosed with Covid-19 by PCR was evaluated at diagnosis. These patients divided into 2 groups as early and advanced disease. Clinical features and laboratory data were compared in terms of severity of disease. Results: In all patients, the most common accompanying disease was coronary artery disease. Cough and headache were the most common complaints. Laboratory values showed low lymphocyte count and high CRP levels in all patients. Twenty four patients in early stage and 26 patients in advanced stage were compared in terms of clinical features and laboratory values. In advanced stage, it was observed that body weight, number of comorbid diseases, age, CRP, procalcitonin, BUN, GGT, fibrinogen, D-dimer and ferritin levels of patients were higher whereas height, serum total protein, albumin and potassium levels were lower when compered with early stage patients (p <0.05). Conclusions: Our data showed that older age, having cough, increased number of comorbid diseases, CRP, BUN, GGT, fibrinogen, D-dimer and ferritin and decresed serum total protein, albumin, potassium levels at the time of diagnosis in COVID-19 patients were associated with advanced stage disease.

26 March 2024 in Ankyra Medical Journal
Verified
Journal Article
Open access
PDF file
NBNurcan Kırıcı Berber
Nurcan Kırıcı Berber
FİFeyza İnceoğlu
Feyza İnceoğlu
MAMehmet Akçiçek
Mehmet Akçiçek
ASAhmet Sarıcı
Ahmet Sarıcı
LDLeman Acun Delen
Leman Acun Delen
IBİlHami Berber
İlHami Berber
Aims: Novel coronavirus-2019 (2019-nCoV) has caused a global pandemic. Fort his reason, our study is to determine the variables of thorax tomography findings and laboratory data after covid 19 pneumonia in cases with severe covid 19 pneumonia and to detect the findings of possible interstitial lung diseases. Methods: In this single-center study, 61 consecutive patients were examined. These patients were admitted to the COVID-19 Pandemic Clinic of Malatya Training and Research Hospital between July 15, 2020 and August 28, 2020 and were hospitalized with a diagnosis of COVID-19 pneumonia. Patients were discharged after the illness, and after 6 months, they applied to the outpatient clinic for follow-up. In this study, we compared the changes in laboratory variables and thorax CT scans at the time of diagnosis and 6 months later. Patients were divided into groups 1 and 2. Group 1: patients who were diagnosed with COVID 19 pneumonia at initial presentation and had thorax CT and laboratory parameters at the time of diagnosis and group 2: patients who presented to the outpatient clinic for 6-month follow-up during the postcovid pneumonia period and had control thorax CT and laboratory parameters. Results: When the laboratory parameters of group 1 and group 2 patients were statistically compared. In addition to the increase in glucose, creatinine, aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transferase, lactate dehydrogenase, aptt, INR, fibrinogen, neutrophil percentage, mean erythrocyte hemoglobin, albumin, the decrease in calcium, sodium, leukocyte, platelet, hemoglobin, lymphocyte count, erythrocyte distribution range variables were found to be statistically significant (p<0.05). In our study, ground glass opacity was seen most frequently in Group 1 Thorax CT and was found in 57 patients. In 10 of these 57 patients, ground-glass opacity was positive on Group 1 and Group 2 Thorax CT, while ground-glass opacity was negative on Group 2 Thorax CT in 47 patients. In 50 patients, consolidation was found on Group 1 Thorax CT and consolidation was positive on Group 1 and Group 2 Thorax CT in 5 patients. The changes in fibrosis, parenchymal band, reticular opacity, traction bronchiectasis, irregular interfaces, ground glass opacity, consolidation, and pulmonary nodule variables in Group 2 Thorax CT were statistically significant (p<0.05). Conclusion: Laboratory data is very important in terms of COVID-19 infection diagnosis, prognosis and guiding treatment. It may be due to the fact that patients with residual abnormalities on control thorax CT after COVID-19 pneumonia were older, had more comorbid diseases, and had severe clinical disease at the time of hospitalization.

12 January 2025 in Journal of Health Sciences and Medicine
Verified
Journal Article
Open access
PDF file
NBNurcan Kırıcı Berber
Nurcan Kırıcı Berber
ZDZeliha Korkmaz Dişli
Zeliha Korkmaz Dişli
LDLeman Acun Delen
Leman Acun Delen
LGLale Şahin Gür
Lale Şahin Gür
AYAzize Yetişgen
Azize Yetişgen
IBİlHami Berber
İlHami Berber
Aims: This study aims to evaluate the efficacy of the serum lactate/albumin ratio (LAR) as a prognostic marker in patients with ventilator-associated pneumonia (VAP) who are hospitalized in the intensive care unit (ICU). Methods: This single-center retrospective observational clinical study was conducted between January 1, 2022, and October 1, 2024. The study group comprised 58 patients admitted to the ICUs of Malatya Training and Research Hospital, Turkiye, with intubation but without a diagnosis of pneumonia at the time of admission. These patients were diagnosed with VAP 48 hours after intubation. The serum LAR was calculated within the first 24 hours after admission to the ICU and correlated with mortality and morbidity. Results: The mean age of the patients was 68 years, with the majority being over 65 years of age. Of the 58 patients included in the study, 43 (74.1%) ultimately succumbed to their illness. The LAR of those who died in the study was significantly higher than that of those who survived. The LAR was identified as a reliable predictor, exhibiting a sensitivity of 83.7% and a specificity of 60% when a cutoff value of 1.13 was applied. The survival time of patients with a LAR of ≤1.13 was significantly longer than that of patients with a ratio of >1.13. Conclusion: In our study, the mortality prediction performance of the LAR in patients with VAP was superior to that of the serum lactate level or serum albumin level alone. Therefore, the LAR may be a useful and readily available prognostic factor for early risk stratification of VAP patients.